Drug Trial Radar · NCT07455955
Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 31, 2026
Primary completion
Jun 3, 2027
Study completion Jul 3, 2028
Sponsor
- Lead sponsor
- Chinese University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are to determine if pharmacogenetic (PG) analysis of an individual enable optimal selection of antiemetic regimen for patients undergoing the first cycle of AC (Adriamycin + Cyclophosphamide) or FEC (Fluorouracil + Epirubicin + Cyclophosphamide) chemotherapy. It also aims to compare the quality of life of patients in the first cycle of AC / FEC chemotherapy with PG analysis. Patients enrolled into this study will be named as "Upfront-PG patients". Outcomes of the Upfront-PG patients in this prospective study will be compared to a historical control group (i.e. the "Non-upfront-PG patients"). The historical control group comprised of patients who were enrolled into a prior study. The latter did not have upfront PG analysis. These Non-upfront-PG patients received Standard antiemetic regimen, with PG analysis performed retrospectively as part of that prior study.
Conditions
- Breast Cancer
Interventions
Standard antiemetic regimen or Olanzapine antiemetic regimenDrug
Standard antiemetic regimen: * Day 1: Aprepitant 125mg QD (once daily); Ondansetron 8mg BD (twice daily); Dexamethasone 12mg QD (Aprepitant, Ondansetron and Dexamethasone to be take 60 minutes before chemotherapy on Day 1) * Days 2 to 3: Aprepitant 80mg QD Olanzapine antiemetic regimen: * Day 1: Aprepitant 125mg QD; Ondansetron 8mg BD; Dexamethasone 12 mg QD; Olanzapine 10mg QD (Aprepitant, Ondansetron and Dexamethasone to be take 60 minutes before chemotherapy on Day 1); Olanzapine 10mg nocte * Days 2 to 3: Aprepitant 80mg QD; Olanzapine 10mg nocte * Days 4-5: Olanzapine 10mg nocte
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Protection (CP)Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.